Advertisement

Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

Published:March 05, 2020DOI:https://doi.org/10.1016/j.jhep.2020.02.028

      Highlights

      • NAFLD-related significant fibrosis predicts the occurrence of type 2 diabetes mellitus and arterial hypertension.
      • The annual incidence of metabolic outcomes is four-times higher in the presence of significant fibrosis.
      • Neither steatosis nor NASH predict the appearance of metabolic outcomes.
      • Hepamet fibrosis score >0.12 is associated with the risk of developing type 2 diabetes mellitus.

      Background & Aims

      Non-alcoholic fatty liver disease (NAFLD) could play a catalytic role in the development of metabolic comorbidities, although the magnitude of this effect in metabolically healthy patients with NAFLD remains unclear. We assessed the role of biopsy-proven NAFLD on the risk of developing type 2 diabetes mellitus (T2DM) and other metabolic comorbidities (arterial hypertension [AHT], and dyslipidemia) in metabolically healthy patients.

      Methods

      We included 178 metabolically healthy—defined by the absence of baseline T2DM, AHT, dyslipidemia—patients with biopsy-proven NAFLD from the HEPAmet Registry (N = 1,030). Hepamet fibrosis score (HFS), NAFLD fibrosis score, and Fibrosis-4 were calculated. Follow-up was computed from biopsy to the diagnosis of T2DM, AHT, or dyslipidemia.

      Results

      During a follow-up of 5.6 ± 4.4 years, T2DM occurred in 9% (16/178), AHT in 8.4% (15/178), low HDL in 9.6% (17/178), and hypertriglyceridemia in 23.6% (42/178) of patients. In multivariate analysis, significant fibrosis predicted T2DM and AHT. Independent variables related to T2DM appearance were significant fibrosis (HR 2.95; 95% CI 1.19–7.31; p = 0.019), glucose levels (p = 0.008), age (p = 0.007) and BMI (p = 0.039). AHT was independently linked to significant fibrosis (HR 2.39; 95% CI 1.14–5.10; p = 0.028), age (p = 0.0001), BMI (p = 0.006), glucose (p = 0.021) and platelets (p = 0.050). The annual incidence rate of T2DM was higher in patients with significant fibrosis (4.4 vs. 1.2 cases per 100 person-years), and increased in the presence of obesity, similar to AHT (4.6 vs. 1.1 cases per 100 person-years). HFS >0.12 predicted the risk of T2DM (25% [4/16] vs. HFS <0.12 4.5% [4/88]; logRank 6.658, p = 0.010).

      Conclusion

      Metabolically healthy patients with NAFLD-related significant fibrosis were at greater risk of developing T2DM and AHT. HFS >0.12, but not NAFLD fibrosis score or Fibrosis-4, predicted the occurrence of T2DM.

      Lay summary

      Patients with biopsy-proven non-alcoholic fatty liver disease and significant fibrosis were at risk of developing type 2 diabetes mellitus and arterial hypertension. The risk of metabolic outcomes in patients with significant fibrosis was increased in the presence of obesity. In addition to liver biopsy, patients at intermediate-to-high risk of significant fibrosis by Hepamet fibrosis score were at risk of type 2 diabetes mellitus.

      Graphical abstract

      Keywords

      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sanyal A.J.
        Past, present and future perspectives in nonalcoholic fatty liver disease.
        Nat Rev Gastroenterol Hepatol. 2019; 16: 377-386
        • Kotronen A.
        • Yki-Järvinen H.
        Fatty liver: a novel component of the metabolic syndrome.
        Arterioscler Thromb Vasc Biol. 2008; 28: 27-38
        • Ampuero J.
        • Aller R.
        • Gallego-Durán R.
        • Banales J.M.
        • Crespo J.
        • García-Monzón C.
        • et al.
        The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
        Aliment Pharmacol Ther. 2018; 48: 1260-1270
        • Yilmaz Y.
        Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?.
        World J Hepatol. 2012; 4: 332
        • Lonardo A.
        • Ballestri S.
        • Marchesini G.
        • Angulo P.
        • Loria P.
        Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.
        Dig Liver Dis. 2015; 47: 181-190
        • Ma J.
        • Hwang S.-J.
        • Pedley A.
        • Massaro J.M.
        • Hoffmann U.
        • Chung R.T.
        • et al.
        Bi-directional analysis between fatty liver and cardiovascular disease risk factors.
        J Hepatol. 2017; 66: 390-397
        • Adams L.A.
        • Anstee Q.M.
        • Tilg H.
        • Targher G.
        Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
        Gut. 2017; 66: 1138-1153
        • Ampuero J.
        • Gallego-Durán R.
        • Romero-Gómez M.
        Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis.
        Rev Esp Enferm Dig. 2015; 107: 10-16
        • Ampuero J.
        • Pais R.
        • Aller R.
        • Gallego-Durán R.
        • Crespo J.
        • García-Monzón C.
        • et al.
        Development and validation of hepamet fibrosis scoring system a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis.
        Clin Gastroenterol Hepatol. 2020; 18: 216-225.e5
        • Angulo P.
        • Hui J.M.
        • Marchesini G.
        • Bugianesi E.
        • George J.
        • Farrell G.C.
        • et al.
        The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
        Hepatology. 2007; 45: 846-854
        • Shah A.G.
        • Lydecker A.
        • Murray K.
        • Tetri B.N.
        • Contos M.J.
        • Sanyal A.J.
        • et al.
        Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.
        Clin Gastroenterol Hepatol. 2009; 7: 1104-1112
        • Subasi C.F.
        • Aykut U.E.
        • Yilmaz Y.
        Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease.
        Eur J Gastroenterol Hepatol. 2015; 27: 137-141
        • Sheth S.G.
        • Flamm S.L.
        • Gordon F.D.
        • Chopra S.
        AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection.
        Am J Gastroenterol. 1998; 93: 44-48
        • Hansen L.
        • Netterstrøm M.K.
        • Johansen N.B.
        • Rønn P.F.
        • Vistisen D.
        • Husemoen L.L.N.
        • et al.
        Metabolically healthy obesity and ischemic heart disease: a 10-year follow-up of the Inter99 study.
        J Clin Endocrinol Metab. 2017; 102: 1934-1942
        • Grundy S.M.
        • Cleeman J.I.
        • Daniels S.R.
        • Donato K.A.
        • Eckel R.H.
        • Franklin B.A.
        • et al.
        Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.
        Circulation. 2005; 112: 2735-2752
        • Bedossa P.
        • FLIP Pathology Consortium
        Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease.
        Hepatology. 2014; 60: 565-575
        • Kleiner D.E.
        • Brunt E.M.
        • Van Natta M.
        • Behling C.
        • Contos M.J.
        • Cummings O.W.
        • et al.
        Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
        Hepatology. 2005; 41: 1313-1321
        • Geiss L.S.
        • Wang J.
        • Cheng Y.J.
        • Thompson T.J.
        • Barker L.
        • Li Y.
        • et al.
        Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012.
        JAMA. 2014; 312: 1218
        • Forouhi N.G.
        • Luan J.
        • Hennings S.
        • Wareham N.J.
        Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000.
        Diabet Med. 2007; 24: 200-207
        • Sinnott S.-J.
        • McHugh S.
        • Whelton H.
        • Layte R.
        • Barron S.
        • Kearney P.M.
        Estimating the prevalence and incidence of type 2 diabetes using population level pharmacy claims data: a cross-sectional study.
        BMJ Open Diabetes Res Care. 2017; 5: e000288
        • Andersson T.
        • Ahlbom A.
        • Magnusson C.
        • Carlsson S.
        Prevalence and incidence of diabetes in Stockholm county 1990-2010.
        PLoS One. 2014; 9: e104033
        • Valenti L.
        • Bugianesi E.
        • Pajvani U.
        • Targher G.
        Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?.
        Liver Int. 2016; 36: 1563-1579
        • Ballestri S.
        • Zona S.
        • Targher G.
        • Romagnoli D.
        • Baldelli E.
        • Nascimbeni F.
        • et al.
        Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.
        J Gastroenterol Hepatol. 2016; 31: 936-944
        • Mantovani A.
        • Byrne C.D.
        • Bonora E.
        • Targher G.
        Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis.
        Diabetes Care. 2018; 41: 372-382
        • Björkström K.
        • Stål P.
        • Hultcrantz R.
        • Hagström H.
        Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease.
        Clin Gastroenterol Hepatol. 2017; 15: 1461-1468
        • Ryoo J.-H.
        • Suh Y.J.
        • Shin H.C.
        • Cho Y.K.
        • Choi J.-M.
        • Park S.K.
        Clinical association between non-alcoholic fatty liver disease and the development of hypertension.
        J Gastroenterol Hepatol. 2014; 29: 1926-1931
        • Huh J.H.
        • Ahn S.V.
        • Koh S.B.
        • Choi E.
        • Kim J.Y.
        • Sung K.-C.
        • et al.
        A prospective study of fatty liver index and incident hypertension: the KoGES-ARIRANG study.
        PLoS One. 2015; 10: e0143560
        • Sung K.-C.
        • Wild S.H.
        • Byrne C.D.
        Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension.
        J Hepatol. 2014; 60: 1040-1045
        • Yeung M.W.
        • Wong G.L.H.
        • Choi K.C.
        • Luk A.O.Y.
        • Kwok R.
        • Shu S.S.T.
        • et al.
        Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes.
        J Hepatol. 2018; 68: 147-156
        • Tabák A.G.
        • Jokela M.
        • Akbaraly T.N.
        • Brunner E.J.
        • Kivimäki M.
        • Witte D.R.
        Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.
        Lancet. 2009; 373: 2215-2221
        • Song Y.S.
        • Hwang Y.-C.
        • Ahn H.-Y.
        • Park C.-Y.
        Comparison of the usefulness of the updated homeostasis model assessment (HOMA2) with the original HOMA1 in the prediction of type 2 diabetes mellitus in Koreans.
        Diabetes Metab J. 2016; 40: 318
        • Chang Y.
        • Jung H.-S.
        • Yun K.E.
        • Cho J.
        • Cho Y.K.
        • Ryu S.
        Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population.
        Am J Gastroenterol. 2013; 108: 1861-1868
        • Sung K.-C.
        • Seo D.-C.
        • Lee S.-J.
        • Lee M.-Y.
        • Wild S.H.
        • Byrne C.D.
        Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese.
        Nutr Metab Cardiovasc Dis. 2019; 29: 489-495
        • Önnerhag K.
        • Hartman H.
        • Nilsson P.M.
        • Lindgren S.
        Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
        Scand J Gastroenterol. 2019; 54: 328-334